MASH & Liver Medication Portfolios
Complete index of unbranded education portals, FDA-approved MASH / HE / LAL-D therapy websites, patient support lines, and Phase 3 pipeline sponsor hubs.
Modern pharmaceutical portfolios often split into three separate websites per company: an unbranded disease site (like Madrigal's TakingOnFattyLiverAndMASH.com or Salix's UnderstandingHE.com), a branded medication portal (like Rezdiffra.com, mash.wegovy.com, or Kanuma.com), and a financial & insurance support hub (like Madrigal Patient Support, NovoCare, or Alexion OneSource). We map all three layers together below so you never miss a support service.
At-a-Glance Map of Major SLD Pharmaceutical Portfolios
| Company | SLD Focus / FDA Status | Unbranded Education | Branded & Support Portals |
|---|---|---|---|
| Madrigal Pharmaceuticals | F2-F3 MASH (FDA-approved Rezdiffra) | TakingOnFattyLiverAndMASH.com (EN + ES + Specialist Finder) | Rezdiffra.com (Real Voices™) • MadrigalPatientSupport.com (1-877-219-7770) |
| Novo Nordisk | F2-F3 MASH (FDA-approved Wegovy) | TruthAboutWeight.com | mash.wegovy.com (Provider Finder) • NovoCare.com |
| Salix / Bausch Health | Cirrhosis — Hepatic Encephalopathy (FDA-approved Xifaxan) | UnderstandingHE.com | Xifaxan.com/he |
| Alexion / AstraZeneca | Rare Monogenic SLD — LAL-D (FDA-approved Kanuma) | LALDSource.com | Kanuma.com • Alexion OneSource™ |
| Eli Lilly & Boehringer Ingelheim | Obesity/T2D & Phase 3 MASH / Cirrhosis Pipelines | Metabolic & CRM trial education | trials.lilly.com, LillyCares.com • MyStudyWindow.com |
| Akero, 89bio/Roche, Inventiva, Sagimet | Phase 3 MASH & F4 Cirrhosis Pipelines (FGF21, pan-PPAR, FASN) | Mechanism & trial overviews | Akero • 89bio • Inventiva • Sagimet |
Verified Live Resources (27)
No resources matched that exact combination of filters.
Know a trusted patient resource we should add, or spotted a moved link? Steatotic Liver Foundation maintains this directory for the entire SLD community. Join our network or help keep patient navigation free for every family.